As the NSABP celebrates its 60th anniversary in 2018, Dr. Harry D. Bear honors the organization's history and accomplishments.

Clinical trials are the pathway to better treatments, better outcomes, and a future without cancer. We, as investigators, need to believe in them, and be willing to offer them to all patients who are eligible....

ASCO's current president explains why he's passionate about precision medicine, as well as the concerns that keep him up at night. 

A trial of aqueous lidocaine to manage painful intercourse for breast cancer survivors was a small study with a great magnitude of benefit. Do we need to wait for more data, or can we start applying these...

Dr. Richard L. Schilsky describes ASCO's Targeted Agent and Profiling Utilization Registry (TAPUR) Study and similar independent studies worldwide.

Only 11% of randomized trials give enough detail to practically use in clinical practice. Here are five ways we can use internet-based communication to make it easier for academic innovators to get credit for...

A journal that aims to be the voice of global oncology has to publish work relating not only to differences in cancer biology due to risk factors, pathogenesis, and pharmacology, but also disparities arising...

More than 100 oncology practices have signed up to participate in ASCO's big data initiative. "We need good data, and lots of it, if we’re to draw meaningful conclusions that can improve patient care," writes...

We have a responsibility to design clinical trials that reflect our patient mix, and to offer hope to all of our patients rather than a select few.